"In our study, we showed that fine needle aspiration (FNA) biopsy material can be a good source for next-generation sequencing (NGS) for patients with metastatic prostate cancer. Based on these ...

Please provide your email address to receive an email when new articles are posted on . Real-world data show that only about 30% to 40% of patients with the most common cancers receive NGS testing.

Advances in next-generation sequencing (NGS) and synthetic DNA technologies are reshaping oncology research by enabling earlier cancer detection, more accurate biomarker discovery, and sensitive ...

Over the past decade, advances in cancer genetics and oncogenomic have profoundly reshaped our understanding of pediatric tumors. Unlike adult cancers, ...

A $4.7 million collaboration led by the National Cancer Centre Singapore will develop a clinical-grade test using AI and ...

The race for early cancer detection is one that physicians have been running for millennia. In one of humanity’s oldest surviving medical texts, the ancient Egyptian physician Imhotep described 46 ...

Life sciences and diagnostics company Revvity has had a busy couple of years, playing a major role in the next-generation sequencing-based screening of newborns to better enable healthcare ...

Twice the output, half the runtime, and half the footprint of the UG 100® with greater flexibility and improved genomic coverage Introducing two new high-throughput instrument configurations ...